Molecular Therapy: Methods & Clinical Development (Jan 2015)

Highly efficient in vitro and in vivo delivery of functional RNAs using new versatile MS2-chimeric retrovirus-like particles

  • Anne Prel,
  • Vincent Caval,
  • Régis Gayon,
  • Philippe Ravassard,
  • Christine Duthoit,
  • Emmanuel Payen,
  • Leila Maouche-Chretien,
  • Alison Creneguy,
  • Tuan Huy Nguyen,
  • Nicolas Martin,
  • Eric Piver,
  • Raphaël Sevrain,
  • Lucille Lamouroux,
  • Philippe Leboulch,
  • Frédéric Deschaseaux,
  • Pascale Bouillé,
  • Luc Sensébé,
  • Jean-Christophe Pagès

Journal volume & issue
Vol. 2

Abstract

Read online

RNA delivery is an attractive strategy to achieve transient gene expression in research projects and in cell- or gene-based therapies. Despite significant efforts investigating vector-directed RNA transfer, there is still a requirement for better efficiency of delivery to primary cells and in vivo. Retroviral platforms drive RNA delivery, yet retrovirus RNA-packaging constraints limit gene transfer to two genome-molecules per viral particle. To improve retroviral transfer, we designed a dimerization-independent MS2-driven RNA packaging system using MS2-Coat-retrovirus chimeras. The engineered chimeric particles promoted effective packaging of several types of RNAs and enabled efficient transfer of biologically active RNAs in various cell types, including human CD34+ and iPS cells. Systemic injection of high-titer particles led to gene expression in mouse liver and transferring Cre-recombinase mRNA in muscle permitted widespread editing at the ROSA26 locus. We could further show that the VLPs were able to activate an osteoblast differentiation pathway by delivering RUNX2- or DLX5-mRNA into primary human bone-marrow mesenchymal-stem cells. Thus, the novel chimeric MS2-lentiviral particles are a versatile tool for a wide range of applications including cellular-programming or genome-editing.